Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

被引：0
|
作者：
Matthias Lang
Thomas Longerich
Chrysanthi Anamaterou
机构：
[1] University Hospital Heidelberg,Department of General
[2] University Hospital Heidelberg,, Visceral
[3] University of Heidelberg, and Transplant Surgery
来源：
Thyroid Research | / 16卷
关键词：
Anaplastic thyroid carcinoma; Vemurafenib; BRAF-inhibitor; Adjuvant targeted therapy; BRAF(V600E)-mutation; Review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
    Lang, Matthias
    Longerich, Thomas
    Anamaterou, Chrysanthi
    THYROID RESEARCH, 2023, 16 (01)
  • [2] BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
    Del Bufalo, Francesca
    Ceglie, Giulia
    Cacchione, Antonella
    Alessi, Iside
    Colafati, Giovanna Stefania
    Carai, Andrea
    Diomedi-Camassei, Francesca
    De Billy, Emmanuel
    Agolini, Emanuele
    Mastronuzzi, Angela
    Locatelli, Franco
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [3] BRAF V600E Inhibition in Anaplastic Thyroid Cancer
    Rosove, Michael H.
    Peddi, Parvin F.
    Glaspy, John A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (07): : 684 - 685
  • [4] BRAF V600E Mutation in Anaplastic Thyroid Carcinoma
    Walts, A. E.
    Pao, A.
    Bose, S.
    LABORATORY INVESTIGATION, 2014, 94 : 161A - 161A
  • [5] BRAF V600E Mutation in Anaplastic Thyroid Carcinoma
    Walts, A. E.
    Pao, A.
    Bose, S.
    MODERN PATHOLOGY, 2014, 27 : 161A - 161A
  • [6] Vemurafenib selectively radiosensitizes BRAF V600E mutant papillary and anaplastic thyroid carcinoma cells
    Robb, Ryan N.
    Yang, Linlin
    Williams, Terence
    CANCER RESEARCH, 2017, 77
  • [7] Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib
    Marks, Asher M.
    Bindra, Ranjit S.
    DiLuna, Michael L.
    Huttner, Anita
    Jairam, Vikram
    Kahle, Kristopher T.
    Kieran, Mark W.
    PEDIATRIC BLOOD & CANCER, 2018, 65 (05)
  • [8] Comment on: Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib
    Bourque, Melissa S.
    Salek, Marta
    Sabin, Noah D.
    Canale, Meredith
    Upadhyaya, Santhosh A.
    PEDIATRIC BLOOD & CANCER, 2021, 68 (04)
  • [9] BRAF V600E Mutation Status in Anaplastic Thyroid Carcinoma
    Nonaka, Daisilke
    Rushton, Sarah
    Burghel, George
    Wallace, Andrew
    LABORATORY INVESTIGATION, 2015, 95 : 139A - 139A
  • [10] BRAF V600E mutation status in anaplastic thyroid carcinoma
    Nonaka, D.
    Rushton, S.
    Burghel, G.
    Wallace, A.
    VIRCHOWS ARCHIV, 2015, 467 : S71 - S71
12345